Search

Drug Profiles Catalysts Company Profiles Impact Events Target
Indication Trials KOL Insight Special Reports All

Drug Impact Events

Date Lead
Company
Event Type Approval
Change
Approval
Likelihood
10/21/14 Omeros (OMER) OMS824 for Schizophrenia Subscribers Only Subscribers Only     Subscribers Only
10/21/14 Salix (SLXP) Xifaxan for Irritable Bowel Syndrome (IBS) Subscribers Only Subscribers Only     Subscribers Only
10/21/14 Otsuka (4768:JP) TAS-102 for Colorectal Cancer (CRC) Subscribers Only Subscribers Only     Subscribers Only
10/21/14 Omeros (OMER) OMS824 for Huntington's Disease Subscribers Only Subscribers Only     Subscribers Only
10/20/14 Novartis (NVS) Cosentyx for Psoriasis Subscribers Only Subscribers Only     Subscribers Only

Upcoming Catalysts

Expected
Date Range
Lead
Company
Drug Expected
Catalyst
10/21/14 Subscribers Only Subscribers Only Regulatory - CHMP (European Panel) Supplemental Filing Results
10/21/14 Subscribers Only Subscribers Only Trial Data - Updated Results
10/21/14 Subscribers Only Subscribers Only Trial Data - Top-Line Results
10/21/14 Subscribers Only Subscribers Only Trial Data - Final Results
10/21/14 Subscribers Only Subscribers Only Trial Data - Updated Results